Advertising Citations Reach Record High: Another Way To Regulate Pharma?
Executive Summary
FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month
You may also be interested in...
Bayer Loses Oversight Of Yaz DTC Ads Under Agreement With States Attorneys General
FDA has oversight over DTC advertising for Bayer’s Yaz contraceptive after the company violated an earlier agreement with state attorneys general.
Yaz ad gets FDA-OK make-over
Bayer is airing a corrective television ad campaign for its oral contraceptive Yaz (drospirenone/ethinyl estradiol), in response to an agency warning letter it received last fall (1"The Pink Sheet," Oct. 13, 2008, p. 21). The campaign will more clearly say Yaz is indicated to treat symptoms for premenstrual dysphoric disorder, not premenstrual syndrome, and moderate, not mild, acne. The ad is markedly different from the 2008 campaign and features one woman talking about the product and indications (with no balloons), Bayer said. It will run through August
Yaz ad gets FDA-OK make-over
Bayer is airing a corrective television ad campaign for its oral contraceptive Yaz (drospirenone/ethinyl estradiol), in response to an agency warning letter it received last fall (1"The Pink Sheet," Oct. 13, 2008, p. 21). The campaign will more clearly say Yaz is indicated to treat symptoms for premenstrual dysphoric disorder, not premenstrual syndrome, and moderate, not mild, acne. The ad is markedly different from the 2008 campaign and features one woman talking about the product and indications (with no balloons), Bayer said. It will run through August